Law360, New York (October 7, 2011, 12:22 PM EDT) -- Pfizer Inc. lodged a patent infringement suit against Watson Pharmaceuticals Inc. and its subsidiaries in Delaware on Thursday in an effort to block it from selling a generic version of painkiller Embeda, a morphine-containing capsule designed to dissuade drug abuse.
The plaintiff filed the complaint after receiving notice in August that Watson had submitted an abbreviated new drug application to the U.S Food and Drug Administration seeking approval to manufacture and sell a generic version of Embeda.
The suit alleges that Watson's ANDA infringes three patents covering Embeda, granted to Pfizer in 2010, and that the company will further infringe the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!